“Open-Label Evaluation of a Novel Skin Brightening System Containing 0.01% Decapeptide-12 in Combination With 20% Bufered Glycolic Acid for the Treatment of Mild to Moderate Facial Melasma”1
- 1.Ramírez S, Carvajal A, Salazar J, Arroyave G, Flórez A, Echeverry H. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermatol. 2013;12(6):e106-10. https://www.ncbi.nlm.nih.gov/pubmed/23839199
Estimated Reading Time: < 1 min read